Excelsior Biopharma (6496) — Financial Flexibility Index
Excelsior Biopharma (6496) has a Financial Flexibility Index of -0.03x as of December 2025. Free cash flow of NT$-20.81 Million (operating CF NT$-22.21 Million minus capex NT$1.40 Million) represents 0% of total liabilities (NT$679.78 Million). Also explore Excelsior Biopharma annual equity growth to track the company's year-over-year net asset growth rate.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
Excelsior Biopharma Financial Flexibility Index (2017–2025)
Historical Financial Flexibility Index trend for Excelsior Biopharma across 9 annual periods. Check Excelsior Biopharma strategic capital allocation to assess the company's strategic physical and investment asset allocation.
Annual Financial Flexibility Index for Excelsior Biopharma (2017–2025)
Year-by-year free cash flow to debt coverage for Excelsior Biopharma. For the full company profile including market capitalisation, see market value of Excelsior Biopharma.
| Year | Flexibility Index | Free Cash Flow (TWD) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2025 | -0.15x | NT$-101.78 Million | NT$-138.72 Million | NT$679.78 Million | ▼ -155.8% |
| 2024 | 0.27x | NT$157.35 Million | NT$-99.80 Million | NT$586.89 Million | ▲ +227.9% |
| 2023 | -0.21x | NT$-99.09 Million | NT$-134.75 Million | NT$472.87 Million | ▼ -901.5% |
| 2022 | 0.03x | NT$13.27 Million | NT$5.49 Million | NT$507.53 Million | ▼ -72.9% |
| 2021 | 0.10x | NT$58.70 Million | NT$55.82 Million | NT$608.90 Million | ▼ -88.8% |
| 2020 | 0.86x | NT$532.43 Million | NT$520.81 Million | NT$617.15 Million | ▲ +241.0% |
| 2019 | -0.61x | NT$-149.36 Million | NT$-169.74 Million | NT$244.06 Million | ▼ -221.5% |
| 2018 | 0.50x | NT$136.46 Million | NT$126.92 Million | NT$270.88 Million | ▼ -53.5% |
| 2017 | 1.08x | NT$367.57 Million | NT$349.47 Million | NT$339.37 Million | — |